Pharmacology · Antipsychotic Drugs

Dopamine Pathways and the Neurobiological Basis of Psychosis

Visual summary of the four dopamine circuits, receptor subtypes, and symptom dimensions of schizophrenia

The dopamine hypothesis of schizophrenia has one central irony: the drug effect that treats the disease and the drug effects that cause most of the side effects are the same pharmacological action — dopamine D2 blockade — occurring in different anatomical locations simultaneously. The four pathway cards show each location and what happens when the same mechanism arrives there.
Two of the four pathways are part of the disease; two are not. The mesolimbic pathway is overactive in psychosis — blockade there is therapeutic. The mesocortical pathway is underactive — blockade there makes things worse. The nigrostriatal and tuberoinfundibular pathways are structurally normal; they produce motor side effects and hyperprolactinemia respectively because the drug cannot be targeted to one pathway at a time.
The receptor table is a tool for predicting side effect profiles before prescribing. D2 column is uniform across all antipsychotics because that is the shared mechanism. The columns to its right — serotonin 5-HT2A, histamine H1, muscarinic M1, and alpha-1 — vary by agent and generate the distinct burden profiles that separate agents from one another.
The serotonin 5-HT2A row in the receptor table is the pharmacological definition of "atypicality." Higher 5-HT2A-to-D2 blockade ratio means lower motor side effect burden and partial mesocortical sparing — the rationale behind second-generation antipsychotics. The tradeoff is in the H1 and 5-HT2C columns, which drive weight gain and metabolic effects.
The three symptom cards at the bottom close a loop with the pathway cards above. Each symptom dimension maps to a specific dopaminergic circuit, which predicts treatment response: positive symptoms respond well, negative and cognitive symptoms respond poorly or not at all, because the underlying pathophysiology is dopamine deficiency rather than excess.

The Four Dopaminergic Pathways

Pathway 1 — Therapeutic Mesolimbic

OriginVentral tegmental area

TargetNucleus accumbens, limbic structures

FunctionReward, motivational salience

In psychosisOveractive → positive symptoms

BlockadeReduces hallucinations and delusions

Pathway 2 — Problem Mesocortical

OriginVentral tegmental area

TargetPrefrontal cortex

FunctionWorking memory, executive function

In psychosisUnderactive → negative symptoms, cognitive deficits

BlockadeWorsens already-deficient pathway

Pathway 3 — Side Effects Nigrostriatal

OriginSubstantia nigra pars compacta

TargetStriatum (caudate and putamen)

FunctionMotor control (lost in Parkinson disease)

In psychosisNormal — not part of disease

BlockadeExtrapyramidal symptoms, tardive dyskinesia

Pathway 4 — Hormonal Tuberoinfundibular

OriginHypothalamic arcuate nucleus

TargetAnterior pituitary

FunctionDopamine tonically inhibits prolactin release

In psychosisNormal — not part of disease

BlockadeHyperprolactinemia → galactorrhea, amenorrhea

Receptor Binding and Clinical Consequences

Receptor	Blockade Consequence	High-Burden Agents	Low-Burden Agents	Clinical Note
D2 (dopamine)	Antipsychotic effect; extrapyramidal symptoms; hyperprolactinemia	All antipsychotics	—	Primary target; occupancy 65–80% needed for effect
5-HT2A (serotonin)	Reduced extrapyramidal symptoms; partial mesocortical dopamine restoration	Clozapine, olanzapine, quetiapine	Haloperidol, fluphenazine	Defines “atypicality” — higher ratio vs D2, lower motor side effect burden
H1 (histamine)	Sedation; weight gain (appetite stimulation)	Clozapine, olanzapine, quetiapine	Aripiprazole, ziprasidone, lurasidone	Major driver of antipsychotic-induced metabolic effects
M1 (muscarinic)	Dry mouth, urinary retention, constipation, cognitive impairment	Clozapine, thioridazine, chlorpromazine	Haloperidol, risperidone, aripiprazole	Central M1 blockade worsens cognition — problem in schizophrenia
Alpha-1 (adrenergic)	Orthostatic hypotension, reflex tachycardia, dizziness	Clozapine, chlorpromazine, iloperidone	Haloperidol, aripiprazole	Requires gradual dose titration; especially hazardous in elderly patients

Three Symptom Dimensions of Schizophrenia

Positive Symptoms

Hallucinations (auditory most common)
Delusions (paranoid most common)
Disorganized thinking and behavior

Substrate: mesolimbic dopamine excess
Response: respond well to antipsychotics

Negative Symptoms

Blunted affect (reduced expressivity)
Alogia (reduced speech)
Avolition (reduced motivation)
Anhedonia, asociality

Substrate: mesocortical dopamine deficiency
Response: respond poorly; may worsen on first-generation antipsychotics

Cognitive Symptoms

Working memory impairment
Attention deficits
Reduced processing speed
Executive function deficits

Substrate: prefrontal dopamine D1 hypostimulation
Response: no approved pharmacological treatment

Key Principle: All antipsychotics block dopamine D2 receptors in all four pathways simultaneously. The therapeutic effect (mesolimbic) and the adverse effects (nigrostriatal, tuberoinfundibular, mesocortical) are all consequences of the same mechanism operating in different anatomical locations.

Second-generation advantage: Adding serotonin 5-HT2A blockade partially restores dopamine tone in the nigrostriatal and mesocortical pathways, reducing motor side effects — but at the cost of increased metabolic adverse effects (H1 and serotonin 5-HT2C blockade driving weight gain and glucose dysregulation).

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Stahl SM	Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed.	Cambridge University Press; 2013:129–237
Seeman P, Lee T, Chau-Wong M, Wong K	Antipsychotic drug doses and neuroleptic/dopamine receptors	Nature. 1976;261(5562):717–719
Howes OD, Kapur S	The dopamine hypothesis of schizophrenia: version III — the final common pathway	Schizophr Bull. 2009;35(3):549–562
Javitt DC, Zukin SR	Recent advances in the phencyclidine model of schizophrenia	Am J Psychiatry. 1991;148(10):1301–1308
Goldman-Rakic PS	The cortical dopamine system: role in memory and cognition	Adv Pharmacol. 1998;42:707–711
Tandon R, Nasrallah HA, Keshavan MS	Schizophrenia, “just the facts” 4. Clinical features and conceptualization	Schizophr Res. 2009;110(1–3):1–23
Kane J, Honigfeld G, Singer J, Meltzer H	Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine	Arch Gen Psychiatry. 1988;45(9):789–796
Nemeth G, Laszlovszky I, Czobor P, et al.	Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia	Lancet. 2017;389(10074):1103–1113
Cella M, Roberts S, Pillny M, et al.	Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses	Br J Psychiatry. 2023;223(1):8–17
Lieberman JA, Stroup TS, McEvoy JP, et al.	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia	N Engl J Med. 2005;353(12):1209–1223
Kapur S, Zipursky R, Jones C, Remington G, Houle S	Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia	Am J Psychiatry. 2000;157(4):514–520
Smart SE, Kepinska AP, Murray RM, MacCabe JH	Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies	Psychol Med. 2021;51(1):44–53